+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Actively Recruiting

Phase Not Applicable
Age: 18Years +
All Genders
ID07521462

Evaluating Dermocosmetic and Laser Treatments for Facial Redness in Erythematotelangiectatic Rosacea Compared to Placebo

Led by ISISPHARMA · Updated on 2026-09-08

50

Participants Needed

1

Research Sites

N/A

Total Duration

AI-Summary

What This Trial Is About

Researchers are evaluating a dermocosmetic product designed to reduce facial redness and visible blood vessels linked to erythematotelangiectatic rosacea. This study compares the dermocosmetic product to a placebo, applied to opposite sides of the face, both alone and alongside vascular laser treatment. The trial is randomized, double-blind, placebo-controlled, and involves about 50 adult participants with mild to severe rosacea. Participants will apply the dermocosmetic product on one side of the face and the placebo on the other side twice daily for two months. After this period, both products continue to be used in combination with three sessions of vascular laser treatment performed at set intervals. This split-face design allows direct comparison of the treatments effects over an eight-month period. During the study, participants will attend regular clinical visits for assessments, including clinical evaluations of redness and blood vessels, standardized scoring, and patient questionnaires. Safety will be closely monitored by tracking local tolerability and any adverse events. The main outcome measured is the change in Investigator Global Assessment IGA scores on each side of the face after eight months of treatment.

CONDITIONS

Brief Title

Dermocosmetic Treatment for Facial Redness in Rosacea With or Without Laser Therapy

Research Team

C

Chloe GOYET, Master degree

A

Amelie CLEMENT, Engineering degree

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here